Project Grant P01CA306849
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $235,491 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) awarded May 1, 2026, with completion targeted for April 30, 2031. This award supports biomedical research training and career development in cancer research aligned with the National Cancer Program's strategic priorities. The research initiative focuses on investigating the biology and phenotypic...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $683,075 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), effective March 24, 2026, with a completion date of February 28, 2031. This research initiative investigates the mitotic functions of 53BP1 (tumor protein p53-binding protein 1) and its negative regulator TIRR (transient receptor potential channel-associated protein of iris),...
- Federal Grant Award Summary New York University School of Medicine received a $466,125 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), awarded May 14, 2026, with completion targeted for April 30, 2028. The grant funds fundamental research investigating the role of incretin mimetics in reducing the risk of development and progression of multiple myeloma (MM) and its precursor condition, monoclonal gammopathy of undetermined significance...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.602M Project Grant award from the National Institute of Environmental Health Sciences under the Medical Library Assistance program (CFDA 93.879) effective September 1, 2025, through August 31, 2029. The project focuses on developing computational methods for analyzing multiplex immunofluorescence (MIF) imaging data of the tumor microenvironment. The research leverages a clinically validated MIF dataset encompassing...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.71M Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 1, 2025 through July 31, 2032. The award supports research on "New Approaches to Targeting Cell Cycle Proteins for Cancer Treatment," which aims to develop improved therapeutic strategies targeting cyclin-dependent kinase (CDK) inhibition in cancer cells. The...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $170,641 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) for the period August 1, 2025 through July 31, 2027. The award supports research training and investigator development focused on advancing understanding of tumor-immune interactions in colorectal cancer through multimodal spatial profiling analysis. The project will utilize highly multiplexed...
- Federal Project Grant Award Summary Mayo Clinic received a $558,016 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded May 8, 2026, with completion targeted for April 30, 2031. The project investigates accelerated biological aging and immunosenescence as drivers of racial disparities in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Multiple Myeloma (MM). The research aims to understand why African American...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $2.86 million Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 19, 2025, with completion targeted for August 31, 2029. The award funds development and validation of CAMPEX (CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles), an innovative diagnostic platform designed to advance cancer detection and monitoring through liquid...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $607,249 under the Cancer Cause and Prevention Research program (CFDA 93.393) effective May 1, 2026, through April 30, 2031. The award supports research investigating the role of the transcription factor MAFG (MAF Basic Leucine Zipper G) in melanocyte transformation and melanoma development. The research addresses non-genetic...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $561,276 project grant under the Cancer Research Manpower program (CFDA 93.398) on September 19, 2025, to support a five-year mentored career development initiative in multiple myeloma (MM) research. The award funds integrated research and training designed to develop an early-stage physician-scientist at Indiana University Indianapolis under the mentorship of Dr. David Allman and Dr. Alfred Garfall at the...
Dana-Farber Cancer Institute, Inc. received a $2.5M Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded June 1, 2026, with completion scheduled for May 31, 2031. This five-year Program Project (P01) grant funds integrated research to identify genetic and immunological mechanisms driving malignant transformation from Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) to active Multiple Myeloma (MM), the second most common hematologic malignancy in the United States. The award supports development of novel biomarkers and early intervention therapies to predict and intercept MM progression in high-risk patient populations. The research initiative comprises three coordinated projects and supporting core facilities leveraging prospective cohort studies and innovative clinical trials encompassing over 60,000 samples with serial follow-up data. Project 1 focuses on discovering, modeling, and validating genetic determinants of transformation through characterization of tumor-intrinsic genomic abnormalities, while Project 2 examines immune determinants affecting transformation risk. The integrated research strategy translates molecular and immunological observations into actionable biomarkers and therapeutic interventions designed to prevent progression to active MM, ultimately advancing precision cancer prevention and early interception strategies in this vulnerable patient population.Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.5m | 5/26/26 |